{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T17:13:52Z","timestamp":1732036432928},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81301394","81471946","81270503"],"award-info":[{"award-number":["81301394","81471946","81270503"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jgar.2016.10.012","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T14:41:13Z","timestamp":1482504073000},"page":"74-81","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010\u20132014)"],"prefix":"10.1016","volume":"8","author":[{"given":"Tian","family":"Meng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuyang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youlan","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanxin","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2016.10.012_bib0005","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jgar.2016.10.012_bib0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2334-13-181","article-title":"Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening","volume":"13","author":"Hahne","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"10 Suppl. 3","key":"10.1016\/j.jgar.2016.10.012_bib0015","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1097\/00004836-200411003-00008","article-title":"Global epidemiology of hepatitis B virus","volume":"38","author":"Custer","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jgar.2016.10.012_bib0020","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1053\/j.gastro.2007.02.039","article-title":"Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B","volume":"132","author":"Ghany","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jgar.2016.10.012_bib0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/jac\/dkm187","article-title":"Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment","volume":"60","author":"Moriconi","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2016.10.012_bib0030","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/368083","article-title":"Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B","volume":"36","author":"Lai","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2016.10.012_bib0035","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Long-term safety of lamivudine treatment in patients with chronic hepatitis B","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jgar.2016.10.012_bib0040","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jgar.2016.10.012_bib0045","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","article-title":"Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"48","author":"Marcellin","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jgar.2016.10.012_bib0050","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jgar.2016.10.012_bib0055","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jgar.2016.10.012_bib0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"van Bommel","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jgar.2016.10.012_bib0065","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1128\/JCM.01518-10","article-title":"Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients","volume":"48","author":"Li","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2016.10.012_bib0070","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/j.1365-2893.2010.01360.x","article-title":"Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection","volume":"18","author":"Liu","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jgar.2016.10.012_bib0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.20016","article-title":"Viral features of lamivudine resistant hepatitis B genotypes A and D","volume":"39","author":"Z\u00f6llner","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jgar.2016.10.012_bib0080","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jgar.2016.10.012_bib0085","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1055-9965.EPI-09-1001","article-title":"Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in mainland China: a community-based study","volume":"19","author":"Yin","year":"2010","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.jgar.2016.10.012_bib0090","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/135965350300800610","article-title":"Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine","volume":"8","author":"Yuen","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2016.10.012_bib0095","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1440-1746.2006.04630.x","article-title":"Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors","volume":"22","author":"Thompson","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jgar.2016.10.012_bib0100","doi-asserted-by":"crossref","first-page":"17413","DOI":"10.1038\/srep17413","article-title":"Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgar.2016.10.012_bib0105","first-page":"282","article-title":"Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: a randomized, double-blind, multicenter clinical study","volume":"21","author":"Zhao","year":"2007","journal-title":"Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi"},{"key":"10.1016\/j.jgar.2016.10.012_bib0110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/infdis\/jiv363","article-title":"Combined analysis of the prevalence of drug-resistant hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE)","volume":"213","author":"Hermans","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2016.10.012_bib0115","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3350\/cmh.2014.20.2.168","article-title":"Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus","volume":"20","author":"Woo","year":"2014","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jgar.2016.10.012_bib0120","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2016.10.012_bib0125","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jgar.2016.10.012_bib0130","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jgar.2016.10.012_bib0135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jgar.2016.10.012_bib0140","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0168-8278(01)00283-5","article-title":"Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?","volume":"36","author":"Buti","year":"2002","journal-title":"J Hepatol"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716516301400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716516301400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T20:47:27Z","timestamp":1658263647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716516301400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":28,"alternative-id":["S2213716516301400"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2016.10.012","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010\u20132014)","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2016.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}